Table of Contents Author Guidelines Submit a Manuscript
International Journal of Vascular Medicine
Volume 2010, Article ID 726207, 9 pages
http://dx.doi.org/10.1155/2010/726207
Clinical Study

Leukocyte Counts, Myeloperoxidase, and Pregnancy-Associated Plasma Protein A as Biomarkers for Cardiovascular Disease: Towards a Multi-Biomarker Approach

1Department of Pathology, Cardiovascular Research Institute Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands
2Department of Radiology, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands
3Department of Cardiology, Orbis Medical Center, P.O. Box 5500, 6130 MB Sittard, The Netherlands
4Department of Methodology and Statistics, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands
5Department of Cardiology, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands
6Department of Internal Medicine, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands

Received 26 February 2010; Accepted 18 March 2010

Academic Editor: Frank R. Arko

Copyright © 2010 M. B. I. Lobbes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. K. Hansson, “Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease,” The New England Journal of Medicine, vol. 352, no. 16, pp. 1685–1695, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. A. J. Lusis, “Atherosclerosis,” Nature, vol. 407, no. 6801, pp. 233–241, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Weber, A. Zernecke, and P. Libby, “The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models,” Nature Reviews Immunology, vol. 8, no. 10, pp. 802–815, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Koenig and N. Khuseyinova, “Biomarkers of atherosclerotic plaque instability and rupture,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 1, pp. 15–26, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. P. M. Ridker, “High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease,” Circulation, vol. 103, no. 13, pp. 1813–1818, 2001. View at Google Scholar · View at Scopus
  6. J. Danesh, S. Lewington, S. G. Thompson et al., “Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis,” Journal of the American Medical Association, vol. 294, no. 14, pp. 1799–1809, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Danesh, R. Collins, P. Appleby, and R. Peto, “Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies,” Journal of the American Medical Association, vol. 279, no. 18, pp. 1477–1482, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. J. W. G. Yarnell, C. C. Patterson, P. M. Sweetnam, and G. D. O. Lowe, “Haemostatic/inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies,” European Heart Journal, vol. 25, no. 12, pp. 1049–1056, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Danesh, J. G. Wheeler, G. M. Hirschfield et al., “C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease,” The New England Journal of Medicine, vol. 350, no. 14, pp. 1387–1397, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. G. D. Smith, R. Harbord, J. Milton, S. Ebrahim, and J. A. C. Sterne, “Does elevated plasma fibrinogen increase the risk of coronary heart disease? Evidence from a meta-analysis of genetic association studies,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 10, pp. 2228–2233, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Baldus, C. Heeschen, T. Meinertz et al., “Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes,” Circulation, vol. 108, no. 12, pp. 1440–1445, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. K. K. Iversen, A. S. Teisner, B. Teisner et al., “Pregnancy associated plasma protein A, a novel, quick, and sensitive marker in ST-elevation myocardial infarction,” American Journal of Cardiology, vol. 101, no. 10, pp. 1389–1394, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Consuegra-Sanchez, S. Fredericks, and J. C. Kaski, “Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk,” Atherosclerosis, vol. 203, no. 2, pp. 346–352, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. L. Teruel, J. Sabater, C. Galeano et al., “The Cockcroft-Gault equation is better than MDRD equation to estimate the glomerular filtration rate in patients with advanced chronic renal failure,” Nefrologia, vol. 27, no. 3, pp. 313–319, 2007. View at Google Scholar · View at Scopus
  15. M. Haim, V. Boyko, U. Goldbourt, A. Battler, and S. Behar, “Predictive value of elevated white blood cell count in patients with preexisting coronary heart disease: the Bezafibrate Infarction Prevention Study,” Archives of Internal Medicine, vol. 164, no. 4, pp. 433–439, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. H. V. Barron, S. D. Harr, M. J. Radford, Y. Wang, and H. M. Krumholz, “The association between white blood cell count and acute myocardial infarction mortality in patients 65 years of age: findings from the cooperative cardiovascular project,” Journal of the American College of Cardiology, vol. 38, no. 6, pp. 1654–1661, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Bayes-Genis, C. A. Conover, M. T. Overgaard et al., “Pregnancy-associated plasma protein A as a marker of acute coronary syndromes,” The New England Journal of Medicine, vol. 345, no. 14, pp. 1022–1029, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. R. K. Schindhelm, L. P. Van der Zwan, T. Teerlink, and P. G. Scheffer, “Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification?” Clinical Chemistry, vol. 55, no. 8, pp. 1462–1470, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Zhang, M.-L. Brennan, X. Fu et al., “Association between myeloperoxidase levels and risk of coronary artery disease,” Journal of the American Medical Association, vol. 286, no. 17, pp. 2136–2142, 2001. View at Google Scholar · View at Scopus
  20. M.-L. Brennan, M. S. Penn, F. Van Lente et al., “Prognostic value of myeloperoxidase in patients with chest pain,” The New England Journal of Medicine, vol. 349, no. 17, pp. 1595–1604, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. D. A. Morrow, M. S. Sabatine, M.-L. Brennan et al., “Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18,” European Heart Journal, vol. 29, no. 9, pp. 1096–1102, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. N. D. Wong, H. Gransar, J. Narula et al., “Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events,” JACC: Cardiovascular Imaging, vol. 2, no. 9, pp. 1093–1099, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. T. J. Mocatta, A. P. Pilbrow, V. A. Cameron et al., “Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction,” Journal of the American College of Cardiology, vol. 49, no. 20, pp. 1993–2000, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Cavusoglu, C. Ruwende, C. Eng et al., “Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome,” American Journal of Cardiology, vol. 99, no. 10, pp. 1364–1368, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Ruef, W. März, and B. R. Winkelmann, “Markers for endothelial dysfunction, but not markers for oxidative stress correlate with classical risk factors and the severity of coronary artery disease. (A subgroup analysis from the Ludwigshafen Risk and Cardiovascular Health Study),” Scandinavian Cardiovascular Journal, vol. 40, no. 5, pp. 274–279, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Lund, Q.-P. Qin, T. Ilva et al., “Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation,” Circulation, vol. 108, no. 16, pp. 1924–1926, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Heeschen, S. Dimmeler, C. W. Hamm, S. Fichtlscherer, M. L. Simoons, and A. M. Zeiher, “Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis,” Journal of the American College of Cardiology, vol. 45, no. 2, pp. 229–237, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Consuegra-Sanchez, I. Petrovic, J. Cosin-Sales, D. W. Holt, M. Christiansen, and J. C. Kaski, “Prognostic value of circulating pregnancy-associated plasma protein-A (PAPP-A) and proform of eosinophil major basic protein (pro-MBP) levels in patients with chronic stable angina pectoris,” Clinica Chimica Acta, vol. 391, no. 1-2, pp. 18–23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Dominguez-Rodriguez, P. Abreu-Gonzalez, M. Garcia-Gonzalez, J. Ferrer, and M. Vargas, “Circulating pregnancy-associated plasma protein a is not an early marker of acute myocardial infarction,” Clinical Biochemistry, vol. 38, no. 2, pp. 180–182, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Wittfooth, Q.-P. Qin, J. Lund et al., “Immunofluorometric point-of-care assays for the detection of acute coronary syndrome-related noncomplexed pregnancy-associated plasma protein A,” Clinical Chemistry, vol. 52, no. 9, pp. 1794–1801, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. Q.-P. Qin, S. Wittfooth, and K. Pettersson, “Measurement and clinical significance of circulating PAPP-A in ACS patients,” Clinica Chimica Acta, vol. 380, no. 1-2, pp. 59–67, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. T. J. Wang, P. Gona, M. G. Larson et al., “Multiple biomarkers for the prediction of first major cardiovascular events and death,” New England Journal of Medicine, vol. 355, no. 25, pp. 2631–2639, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Varo, J. A. De Lemos, P. Libby et al., “Soluble CD40L: risk prediction after acute coronary syndromes,” Circulation, vol. 108, no. 9, pp. 1049–1052, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Ardigo, T. L. Assimes, S. P. Fortmann et al., “Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease,” Physiological Genomics, vol. 31, no. 3, pp. 402–409, 2007. View at Publisher · View at Google Scholar · View at Scopus